Investment ThemesDetailed Quotes
Top Gainers Yesterday
Watchlist
- 0.510
- -0.001-0.12%
Close Dec 20 16:00 ET
0.511High0.508Low
0.510Open0.510Pre Close1.71BVolume139RiseLossP/E (Static)5.52BTurnover140Flatline0.13%Turnover Ratio251.33BMarket Cap236Fall241.09BFloat Cap
Constituent Stocks: 630Top Rising: ELIQQ+0.00%
Sign in to post a comment
$Quantum Computing (QUBT.US)$ Look at candle pattern, it might just pull up to at least 22 again. If it does pull up then will test 27.
1
$MicroStrategy (MSTR.US)$ merry Christmas bulls! 🥱
MicroStrategy’s $42B BTC buy gives Ponzi schemes a bad name
$Bitcoin (BTC.CC)$
MicroStrategy’s $42B BTC buy gives Ponzi schemes a bad name
$Bitcoin (BTC.CC)$
32
are you still crying nobody is buying MSTR
$Psyence Biomedical (PBM.US)$ Beware of NUKK as well. This is downright manipulation before offer.
Aptose Biosciences Inc. (APTO) is a clinical-stage biotechnology company specializing in developing targeted therapies for hematologic malignancies.
Factors Influencing a Potential Rebound:
1. Clinical Developments:
• Tuspetinib Progress: Aptose’s lead compound, tuspetinib, has shown promise in treating acute myeloid leukemia (AML). Recent preclinical data demonstrate its unique mechanism of action and potential effectiveness, especially when combined with venetoclax.
2. Financi...
Factors Influencing a Potential Rebound:
1. Clinical Developments:
• Tuspetinib Progress: Aptose’s lead compound, tuspetinib, has shown promise in treating acute myeloid leukemia (AML). Recent preclinical data demonstrate its unique mechanism of action and potential effectiveness, especially when combined with venetoclax.
2. Financi...
1
$Aptose Biosciences (APTO.US)$
Aptose Biosciences Inc. has announced the publication of preclinical data in the Cancer Research Communications journal, detailing the unique mechanism of action of their lead compound, tuspetinib (TUS), and its potential in treating acute myeloid leukemia (AML).
Key Findings:
• Selective Kinase Inhibition: Tuspetinib targets specific oncogenic kinases associated with AML, including SYK, JAK1/2, RSK2, mutant KIT, and both wild-type and mutant forms of FL...
Aptose Biosciences Inc. has announced the publication of preclinical data in the Cancer Research Communications journal, detailing the unique mechanism of action of their lead compound, tuspetinib (TUS), and its potential in treating acute myeloid leukemia (AML).
Key Findings:
• Selective Kinase Inhibition: Tuspetinib targets specific oncogenic kinases associated with AML, including SYK, JAK1/2, RSK2, mutant KIT, and both wild-type and mutant forms of FL...
2
$Tonix Pharmaceuticals (TNXP.US)$ Potential re-entry after offering is settled. Assuming they are riding on catalysts to counteract dilution. TNX-2900, & Acute Stress Disorder are phase 2 ready, the FDA letter for Fibro is in 10 days
6
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$SoundHound AI (SOUN.US)$ 24.50,the next target for all😁😁😁
$Tonix Pharmaceuticals (TNXP.US)$ Hope they issue these new shares at 50c or 60c. They're trying to get some more cash for whatever they're working on
2
No comment yet
delavie : even when 150 mil worth of stocks would be sold?